Drug profile · INN
lurbinectedin
ZEPZELCA
lurbinectedin (ZEPZELCA) is a dna negative modulator. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — lurbinectedin
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 14
- Data quality
- 0.89
Quick answer
lurbinectedin (ZEPZELCA) is a dna negative modulator. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA negative modulator
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lurbinectedin?
lurbinectedin (ZEPZELCA) is a dna negative modulator. Associated with Jazz Pharmaceuticals Ireland Limited. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for lurbinectedin?
ZEPZELCA is a marketed brand name for lurbinectedin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lurbinectedin?
lurbinectedin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.